• At Novavax’s 2026 Annual Meeting, nearly half of shareholders opposed the executive compensation package and there was strong opposition to three Board nominees, prompting its largest shareholder, Shah Capital, to publicly call out management’s operational shortcomings and demand urgent change.
• This unusually high level of shareholder pushback shines a light on governance and execution concerns that now sit alongside the company’s scientific and commercial priorities.
• With this backdrop of shareholder unrest and calls for board and operational reform, we’ll explore how it could reshape Novavax’s investment narrative.

Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

Novavax Investment Narrative Recap

To own Novavax today, you really have to believe its vaccine platform and partnerships can convert into sustainable cash flow despite recent volatility in revenues and earnings. The immediate catalyst many investors are watching is execution on upcoming earnings and commercial delivery for its COVID and flu portfolio, while a key risk now is whether governance friction and shareholder pressure slow or complicate that execution. The latest shareholder revolt is material here because it directly targets management’s operational track record.

The most directly relevant development is Shah Capital’s public criticism following the 2026 Annual Meeting, where nearly half of shareholders rejected Novavax’s executive pay and opposed several directors. This lands on top of earlier activism that questioned leadership’s handling of the Sanofi deal and broader operations at a time when milestone and royalty streams are central to the thesis. For a stock whose catalysts depend on partners and precise delivery, rising governance risk is now impossible to ignore.

Yet beneath the science, one of the biggest things investors should now watch is how ongoing shareholder unrest could affect Novavax’s ability to execute on...

Novavax's narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 55% upside to its current price.

Exploring Other Perspectives

While consensus focused on execution and partner risk, the most optimistic analysts once modeled 2028 earnings of about US$38.4 million, which now looks far less certain after this governance shock.

Explore 3 other fair value estimates on Novavax - why the stock might be worth just $13.78!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Novavax research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.